Open AccessRole of tau deposition in early cognitive decline in Down syndrome
Author(s) -
Hartley Sigan L.,
Handen Benjamin L.,
Tudorascu Dana,
Lee Laise,
Cohen Annie,
PiroGambetti Brianna,
Zammit Matthew,
Klunk William,
Laymon Charles,
Zaman Shahid,
Ances Beau M.,
Sabbagh Marwan,
Christian Bradley T.
Publication year - 2022
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1002/dad2.12256
Subject(s) - episodic memory , psychology , neurodegeneration , positron emission tomography , standardized uptake value , biomarker , medicine , cognition , neuroscience , audiology , disease , chemistry , biochemistry
Drawing on the amyloid/tau/neurodegeneration (AT[N]) model, the study examined whether the tau positron emission tomography (PET) biomarker [ 18 F]AV‐1451 was associated with episodic memory problems beyond what was predicted by the amyloid beta (Aβ) PET in Down syndrome (DS). Methods Data from 123 non‐demented adults with DS ( M = 47 years, standard deviation = 6.34) were analyzed. The Cued Recall Test assessed episodic memory. Tau PET standardized update value ratio (SUVR) was assessed across Braak regions as continuous and binary (high tau [T H ] vs. low tau [T L ]) variable. Global PET Aβ SUVR was assessed as binary variable (Aβ– vs. Aβ+). Results In models adjusting for controls, tau SUVR was negatively associated with episodic memory performance in the Aβ+ but not Aβ– group. The Aβ+/T H group evidenced significantly worse episodic memory than the Aβ+/T L group. Discussion Similar to late‐onset and autosomal dominant Alzheimer's disease (AD), high tau was an indicator of early prodromal AD in DS.